July 21 (Reuters) – Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment, sending its shares down 14% in premarket trading.
The trial was designed to characterize the dose-response relationship of the drug tebapivat in sickle cell disease and evaluate whether its profile was meaningfully differentiated relative to other drugs from its class.
Over the 12-week treatment period, improvements in hemoglobin levels and hemolysis – premature destruction of red blood cells – were observed across all tebapivat dose levels.
However, the trial did not demonstrate the level of differentiation required to support continued development, said the company.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
Comments